An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the company ...